Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.
about
Choice and Design of Adjuvants for Parenteral and Mucosal VaccinesCross-presentation of IgG-containing immune complexesThe Yin and Yang of Toll-like receptors in cancerThe effects of TLR activation on T-cell development and differentiationAntitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentationEffect of vaccine administration modality on immunogenicity and efficacy.Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formationThermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies.Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses.Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells.CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery.TLR9 bone marrow chimeric mice define a role for cerebral TNF in neuroprotection induced by CpG preconditioning.Strategies for intranasal delivery of vaccinesThe Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.Harnessing human plasmacytoid dendritic cells as professional APCs.Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response.Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy.Interferon regulatory factor 3 in adaptive immune responses.Intratumoral immunotherapy for melanoma.Biological Response Modifier in Cancer Immunotherapy.Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors.Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivoAntigen cross-presentation by dendritic cell subsets: one general or all sergeants?CD14/TLR4 priming potentially recalibrates and exerts anti-tumor efficacy in tumor associated macrophages in a mouse model of pancreatic carcinoma.Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease.Enhancement of immunomodulative effect of lactic acid bacteria on plasmacytoid dendritic cells with sucrose palmitate.Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity.Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation.Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.Association of self-DNA mediated TLR9-related gene, DNA methyltransferase, and cytokeratin protein expression alterations in HT29-cells to DNA fragment length and methylation status.Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity
P2860
Q26783488-95EB8674-F876-4F6A-B110-2B141918BDD8Q26825801-6F0D144A-E6C6-4EEF-B94E-98CDB1D9D729Q26851526-83F2D078-D313-4991-A6A1-16FE0C8F1AD6Q27001581-15114DC4-2436-42C4-99FD-1135A7A46E11Q27026193-65C9F6B1-EBB2-454E-A4C7-F2041D0A0742Q27692376-1B212488-3BC0-473C-8B3D-451EE821BBB1Q28393754-2A8DD542-3192-4E1D-878F-686DD6AE88A6Q30363372-48867EDA-4B48-4899-BF04-F07E50D5B8AFQ33617905-77712A94-5743-4B1B-AA87-A80512FB60D5Q33758166-06FF5748-159B-4FED-88EB-1BA594532ACAQ34048170-39E1CF85-48DF-4BDB-821B-F8FE3368546FQ34646599-94293F0F-3C28-46DD-8760-8C1DCDC51191Q36395752-A036412C-AFF9-4E86-B2B3-9FEB2E3AA164Q36459095-868BDE51-BE50-4B79-99CF-9F86F4F4F201Q36514771-45352E1C-5919-4E56-B411-CFCBCD3B653DQ36820908-C27A8725-316C-4390-93C8-1BB6B0DD6F3DQ37980404-B5941983-3945-492D-9E9F-020B3EB68C70Q38103581-02D4DCAF-F19F-423D-A6C0-4570E6E977F8Q38176613-5D2EBA3D-95EA-4FC9-BC2D-210D9EF53E9DQ38206571-D092E5A2-1181-4A7A-AAAA-296F7AB36B63Q38216206-F0022C0C-EBA4-4E06-8357-A9B98D6F5F1DQ38518518-2383B458-59D6-43A0-8EFA-F4C7D3AC2EB5Q38848213-A4B3D04C-650D-4E18-AAC4-AB6E59EDA7C7Q38946861-E2DED0B8-1E70-4D05-A234-AE589BC71F2BQ39020471-3408F2BB-41E9-49F8-AC73-6A042B52C899Q41997533-A113699C-E97F-4402-BF31-3EFE194D84ABQ42245307-9E8BB066-D99A-40F7-AD67-ED4AAA4081B4Q42364984-FEE56367-0611-4005-BF61-8A8C4B40EFE0Q42918751-E63CC09B-3C4A-4FEC-B2D4-914F2DFCA052Q49912122-5D9B97C3-10F5-4609-9C2C-F795EB86834FQ50863789-039E7553-A637-454F-81FF-70A3CB68CDC9Q51050849-D37E6A88-88C5-4369-8948-42E94BBE9BF2Q54265746-74CC5D7E-88B1-491D-B7E2-B21FA0816737Q54331419-AA22A761-CF73-4CD4-B6CD-138AD80094CFQ58780459-FC6A5365-94C6-417B-B536-FB5010E7B2EC
P2860
Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Immune adjuvant efficacy of Cp ...... plasmacytoid dendritic cells.
@en
Immune adjuvant efficacy of Cp ...... plasmacytoid dendritic cells.
@nl
type
label
Immune adjuvant efficacy of Cp ...... plasmacytoid dendritic cells.
@en
Immune adjuvant efficacy of Cp ...... plasmacytoid dendritic cells.
@nl
prefLabel
Immune adjuvant efficacy of Cp ...... plasmacytoid dendritic cells.
@en
Immune adjuvant efficacy of Cp ...... plasmacytoid dendritic cells.
@nl
P2093
P2860
P50
P1433
P1476
Immune adjuvant efficacy of Cp ...... plasmacytoid dendritic cells.
@en
P2093
Edith M Janssen
Gosse J Adema
Jori Wagenaars
Louis Boon
Martijn H den Brok
Melissa Wassink
Susan Togher
Theo J Ruers
Zacharias Garcia
P2860
P304
P356
10.1158/0008-5472.CAN-11-2154
P407
P577
2011-07-25T00:00:00Z